Lucid Diagnostics Valuation
| LUCD Stock | USD 0.79 0.02 2.60% |
Lucid Diagnostics is undervalued. Lucid Diagnostics secures a last-minute Real Value of $1.66 per share. The latest price of the firm is $0.79. Our model forecasts the value of Lucid Diagnostics from analyzing the firm fundamentals such as Operating Margin of (9.98) %, return on equity of -10.08, and Shares Outstanding of 59.34 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Lucid Diagnostics' valuation include:
Price Book 2.159 | Enterprise Value 101.1 M | Enterprise Value Ebitda (0.67) | Price Sales 11.1262 | Enterprise Value Revenue 24.1355 |
Undervalued
Today
Please note that Lucid Diagnostics' price fluctuation is very risky at this time. Calculation of the real value of Lucid Diagnostics is based on 3 months time horizon. Increasing Lucid Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Lucid stock is determined by what a typical buyer is willing to pay for full or partial control of Lucid Diagnostics. Since Lucid Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lucid Stock. However, Lucid Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.79 | Real 1.66 | Target 4.36 | Hype 0.79 | Naive 0.75 |
The real value of Lucid Stock, also known as its intrinsic value, is the underlying worth of Lucid Diagnostics Company, which is reflected in its stock price. It is based on Lucid Diagnostics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Lucid Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Lucid Diagnostics helps investors to forecast how Lucid stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lucid Diagnostics more accurately as focusing exclusively on Lucid Diagnostics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Lucid Diagnostics' intrinsic value based on its ongoing forecasts of Lucid Diagnostics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Lucid Diagnostics' closest peers. If more than one evaluation category is relevant for Lucid Diagnostics we suggest using both methods to arrive at a better estimate.
Lucid Diagnostics Cash |
|
Lucid Valuation Trend
Comparing Lucid Diagnostics' enterprise value against its market capitalization is a good way to estimate the value of Lucid Diagnostics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Lucid Diagnostics Total Value Analysis
Lucid Diagnostics is now forecasted to have valuation of 101.1 M with market capitalization of 46.61 M, debt of 15.26 M, and cash on hands of 34.46 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Lucid Diagnostics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
101.1 M | 46.61 M | 15.26 M | 34.46 M |
Lucid Diagnostics Investor Information
About 61.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.12. Lucid Diagnostics had not issued any dividends in recent years. Based on the key indicators related to Lucid Diagnostics' liquidity, profitability, solvency, and operating efficiency, Lucid Diagnostics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Lucid Diagnostics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lucid Diagnostics has an asset utilization ratio of 8.9 percent. This indicates that the Company is making $0.089 for each dollar of assets. An increasing asset utilization means that Lucid Diagnostics is more efficient with each dollar of assets it utilizes for everyday operations.Lucid Diagnostics Ownership Allocation
Lucid Diagnostics maintains a total of 59.34 Million outstanding shares. Lucid Diagnostics secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 60.83 % of Lucid Diagnostics outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Lucid Diagnostics Profitability Analysis
The company reported the previous year's revenue of 2.43 M. Net Loss for the year was (52.67 M) with loss before overhead, payroll, taxes, and interest of (3.24 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Lucid Diagnostics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Lucid Diagnostics and how it compares across the competition.
About Lucid Diagnostics Valuation
The stock valuation mechanism determines Lucid Diagnostics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Lucid Diagnostics. We calculate exposure to Lucid Diagnostics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lucid Diagnostics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -3.6 M | -3.4 M | |
| Pretax Profit Margin | (21.69) | (22.78) | |
| Operating Profit Margin | (19.97) | (20.97) | |
| Net Loss | (21.69) | (22.78) | |
| Gross Profit Margin | (1.46) | (1.54) |
Lucid Diagnostics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Lucid Diagnostics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 41.8 M |
Lucid Diagnostics Current Valuation Indicators
Valuation refers to the process of determining the present value of Lucid Diagnostics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Lucid we look at many different elements of the entity such as Lucid's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Lucid Diagnostics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Lucid Diagnostics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Lucid Diagnostics' worth.Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |